Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.90B
Market cap1.90B
Price-Earnings ratio
-5.02
Price-Earnings ratio-5.02
Dividend yield
—
Dividend yield—
Average volume
1.43M
Average volume1.43M
High today
$32.63
High today$32.63
Low today
$31.56
Low today$31.56
Open price
$32.56
Open price$32.56
Volume
495.98K
Volume495.98K
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $31.76, with a market capitalization of 1.9B. The stock trades at a price-to-earnings (P/E) ratio of -5.02.

During the trading session on 2026-11-12, Agios(AGIO) shares reached a daily high of $32.63 and a low of $31.56. At a current price of $31.76, the stock is +0.6% higher than the low and still -2.7% under the high.

Trading activity shows a volume of 495.98K, compared to an average daily volume of 1.43M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

Simply Wall St 2d
How Investors May Respond To Agios Pharmaceuticals Earnings Improve As FDA Review Extends

Agios Pharmaceuticals reported third quarter 2026 revenue of US$55.39 million and a net loss of US$65.05 million, while the FDA extended the PDUFA goal date for...

How Investors May Respond To Agios Pharmaceuticals Earnings Improve As FDA Review Extends
TipRanks 4d
Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty - TipRanks

...

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty - TipRanks
Simply Wall St 5d
Agios Pharmaceuticals, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Agios Pharmaceuticals, Inc. ( ) defied analyst predictions to release its third-quarter results, which were ahead of market expectations. Revenues beat expectat...

Agios Pharmaceuticals, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

Simply Wall St 7d
Is Agios Pharmaceuticals A Bargain Following Record Revenue And An FDA Review Delay?

Agios Pharmaceuticals (AGIO) just packed several developments into one stretch. Record third quarter revenue from mitapivat in thalassemia, a longer FDA review...

Is Agios Pharmaceuticals A Bargain Following Record Revenue And An FDA Review Delay?

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.